Topic: Ebola

Health officials are in talks to deploy Merck & Co.’s experimental Ebola vaccine against a new outbreak in Congo.

Even as the WHO said last year that the deadly Ebola outbreak was no longer an international emergency, vaccine experts continue to press officials to not let up in the fight against the virus.

On the heels of crushing Phase III results for its pancreatic cancer candidate, NewLink Genetics has won a lifeline from the U.S. government. The biotech nabbed up to $76 million in BARDA funding to advance its Merck-licensed Ebola vaccine.

On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.

NewLink Genetics is heating up as it bags a $2.8 million contract from the DOD’s Defense Threat Reduction Agency to develop a multivalent filovirus vaccine.